Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection - PubMed (original) (raw)
. 1992 Aug 1;149(3):972-80.
Affiliations
- PMID: 1634779
Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection
D E Speiser et al. J Immunol. 1992.
Abstract
The TCR-alpha beta of CTL recognize peptide Ag in association with MHC class I molecules. TCR binding should be highly specific to guarantee pathogen specificity and to avoid self-reactivity. Therefore, the in vivo relevance of T cells exhibiting cross-reactivities in vitro and the respective role of the TCR affinities involved are not clear. To analyze high and low avidity T cell activities both in vitro and in vivo, we investigated primary and clonal CTL responses specific for the lymphocytic choriomeningitis virus nucleoprotein 118-126 epitope in association with the two closely related H-2Ld or H-2Lq molecules. As expected, we found highly specific class I-allele-restricted CTL responses when antiviral protection or immunopathology in vivo and lysis of virus infected target cells in vitro were analyzed. In contrast, the CTL were MHC crossreactive and thus considerably less discriminatory against targets expressing high MHC-peptide densities and in proliferation assays. The data show that relatively high TCR avidities are required for virus neutralization in vivo, in contrast to in vitro analyses of peptide-coated target cells or proliferative T cell responses that may engage TCR of low avidity and broad specificity and therefore may not reflect biologically relevant TCR avidities.
Similar articles
- In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
von Herrath MG, Coon B, Lewicki H, Mazarguil H, Gairin JE, Oldstone MB. von Herrath MG, et al. J Immunol. 1998 Nov 1;161(9):5087-96. J Immunol. 1998. PMID: 9794447 - CTL escape viral variants. I. Generation and molecular characterization.
Lewicki H, Tishon A, Borrow P, Evans CF, Gairin JE, Hahn KM, Jewell DA, Wilson IA, Oldstone MB. Lewicki H, et al. Virology. 1995 Jun 20;210(1):29-40. doi: 10.1006/viro.1995.1314. Virology. 1995. PMID: 7793078 - Lessons from T cell responses to virus induced tumours for cancer eradication in general.
Melief CJ, Kast WM. Melief CJ, et al. Cancer Surv. 1992;13:81-99. Cancer Surv. 1992. PMID: 1423326 Review. - Molecular mechanisms and biological significance of CTL avidity.
Snyder JT, Alexander-Miller MA, Berzofskyl JA, Belyakov IM. Snyder JT, et al. Curr HIV Res. 2003 Jul;1(3):287-94. doi: 10.2174/1570162033485230. Curr HIV Res. 2003. PMID: 15046253 Review.
Cited by
- Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.
Gilfillan CB, Hebeisen M, Rufer N, Speiser DE. Gilfillan CB, et al. Eur J Immunol. 2021 Jun;51(6):1348-1360. doi: 10.1002/eji.202049016. Epub 2021 Mar 30. Eur J Immunol. 2021. PMID: 33704770 Free PMC article. Review. - High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
Carretero-Iglesia L, Couturaud B, Baumgaertner P, Schmidt J, Maby-El Hajjami H, Speiser DE, Hebeisen M, Rufer N. Carretero-Iglesia L, et al. Front Immunol. 2020 Jan 8;10:3016. doi: 10.3389/fimmu.2019.03016. eCollection 2019. Front Immunol. 2020. PMID: 31969886 Free PMC article. - Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.
Audehm S, Glaser M, Pecoraro M, Bräunlein E, Mall S, Klar R, Effenberger M, Albers J, Bianchi HO, Peper J, Yusufi N, Busch DH, Stevanović S, Mann M, Antes I, Krackhardt AM. Audehm S, et al. Front Immunol. 2019 Jun 28;10:1485. doi: 10.3389/fimmu.2019.01485. eCollection 2019. Front Immunol. 2019. PMID: 31316521 Free PMC article. - Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect.
Du W, Mohammadpour H, O'Neill RE, Kumar S, Chen C, Qiu M, Mei L, Qiu J, McCarthy PL, Lee KP, Cao X. Du W, et al. Oncoimmunology. 2017 Nov 16;7(3):e1397247. doi: 10.1080/2162402X.2017.1397247. eCollection 2018. Oncoimmunology. 2017. PMID: 29399396 Free PMC article. - TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.
Allard M, Couturaud B, Carretero-Iglesia L, Duong MN, Schmidt J, Monnot GC, Romero P, Speiser DE, Hebeisen M, Rufer N. Allard M, et al. JCI Insight. 2017 Jul 20;2(14):e92570. doi: 10.1172/jci.insight.92570. eCollection 2017 Jul 20. JCI Insight. 2017. PMID: 28724801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials